



Bob Leibowitz, M.D.
DIPLOMATE
AMERICAN BOARDS OF INTERNAL MEDICINE,
MEDICAL ONCOLOGY AND HEMATOLOGY
Subspecialty of Prostate Cancer

BOB LEIBOWITZ, M.D.

(A.K.A. DR. BOB)

DIPLOMATE, AMERICAN BOARDS OF MEDICAL ONCOLOGY,
HEMATOLOGY AND INTERNAL MEDICINE (Triple Boarded)

FELLOWSHIP IN ONCOLOGY AND HEMATOLOGY AT BETH ISRAEL & PETER
BENT BRIGHAM HOSPITALS, PART OF HARVARD MEDICAL SCHOOL

RESEARCH FELLOW IN MEDICINE, 1973-1975 and
CLINICAL INSTRUCTOR, 1973-1975, HARVARD MEDICAL SCHOOL

- Father of noninvasive treatments for prostate cancer.

- Is internationally recognized as one of the leaders in clinical prostate cancer research and therapy. Compassionate Oncology protocols are used throughout the USA and all over the world.

- Coined the terms, popularized, and pioneered treatment with his Triple Hormone Blockade®/Leibowitz protocol, followed by treatment with Proscar, 5 mg once a day, so-called Finasteride Maintenance® therapy, since Dr. Bob “so-called” it by this name. Since 1991, Dr. Bob has been recommending this treatment as sole therapy for so-called clinically localized prostate cancer.

- Develops, implements, and modifies constantly evolving, effective, state-of-the-art treatments in order to treat and/or control all stages of prostate cancer.

- Was the first to use and pioneered low-dose weekly Taxotere/Emcyt/carboplatinum chemotherapy, 3 weeks on, 1 week off, beginning in 1998.
- Was the first to use, and pioneered high-dose testosterone replacement therapy for very selected patients with prostate cancer.
- Conceived, developed, and pioneered a highly effective prostate cancer antiangiogenic cocktail.
- Beginning in 1997, first to recommend using 3 Casodex a day rather than the standard dose of 1 a day as the antiandrogen of choice for patients treated with Triple Hormone Blockade®/Leibowitz protocol.
- Visiting Professor, Lectures, September 2002 - Four Venues in Germany; Montabaur, University of Munich, Convention of German Prostate Cancer Support Groups, Hanover Keynote Speaker, Prostate Cancer Symposium, Helios Clinic, Berlin.
- Never recommends re-using any antiandrogen (including Casodex, flutamide, or nilutamide) a second time. Instead, advises using the adrenolytic agents, ketoconazole or Cytadren, or the most effective form of hormone blocking in this setting (opinion), ethinyl estradiol. Initially, antiandrogens kill prostate cancer cells. Over time, there are mutations and antiandrogens cause prostate cancer cells to grow.

®Triple hormone blockade, triple androgen blockade, and finasteride maintenance are the registered trademarks of Robert L. Leibowitz, M.D.